OCTAGON CAPITAL ADVISORS LP
Q4 2021 Form 13-F
NEW YORK, NEW YORK
CIK 0001839435
· CRD 306424
· SEC-registered investment adviser
$513.9M Reported Value Total
OCTAGON CAPITAL ADVISORS LP reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $1,116,417,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $1.2B gross asset value
Hedge Fund: $975.2M · Private Equity Fund: $200.1M
Source: Form ADV filed 2026-03-20
Reported value
$513.9M
Quarter over quarter
-10.5%
Holdings
28
Top-10 concentration
78.0%
Key People
Form ADV owners & control persons
Ting (nmn) Jia
FOUNDER, PORTFOLIO MANAGER, AND LIMITED PARTNER
Justin M Hirsch
CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2021 13F record
Q4 2021 13F filing summary
| Period of report | December 31, 2021 |
|---|---|
| Filed | February 14, 2022 |
| Form | 13F-HR |
| Reported value | $513.9M |
| Positions | 28 |
| Change in reported value | +26.5% |
| New positions | 6 |
| Exited positions | 8 |
| Position turnover | 38.9% |
| Top-10 concentration | 78.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
29 | $903.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
26 | $823.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
26 | $659.8M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
30 | $455.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
34 | $516.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $607.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
41 | $642.9M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
44 | $636.3M |
|
Q1 2024 13F
Filed May 15, 2024
|
56 | $834.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
33 | $625.0M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
35 | $650.9M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
40 | $718.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
35 | $695.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
32 | $642.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
35 | $579.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
20 | $374.7M |
|
Q1 2022 13F
Filed May 16, 2022
|
24 | $462.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
28 | $513.9M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
30 | $406.1M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | APLS APELLIS PHARMACEUTICALS INC | $95.5M | 18.59% |
| 2 | RCUS ARCUS BIOSCIENCES INC | $84.8M | 16.5% |
| 3 | NBP I MAB | $49.7M | 9.68% |
| 4 | FDMT 4D MOLECULAR THERAPEUTICS IN | $34.0M | 6.62% |
| 5 | BBIO BRIDGEBIO PHARMA INC | $29.5M | 5.74% |
| 6 | CLDX CELLDEX THERAPEUTICS INC NEW | $29.4M | 5.73% |
| 7 | ITOS ITEOS THERAPEUTICS INC | $21.0M | 4.08% |
| 8 | KROS KEROS THERAPEUTICS INC | $19.9M | 3.87% |
| 9 | STOK STOKE THERAPEUTICS INC | $18.8M | 3.66% |
| 10 | VERA VERA THERAPEUTICS INC | $17.9M | 3.49% |
| 11 | GOSS GOSSAMER BIO INC | $17.1M | 3.33% |
| 12 | ARVN ARVINAS INC | $14.7M | 2.85% |
| 13 | IPSC CENTURY THERAPEUTICS INC | $11.1M | 2.17% |
| 14 | RNA AVIDITY BIOSCIENCES INC | $10.6M | 2.07% |
| 15 | KDNY CHINOOK THERAPEUTICS INC | $8.2M | 1.59% |
| 16 | RXDX PROMETHEUS BIOSCIENCES INC | $7.9M | 1.54% |
| 17 | DYN DYNE THERAPEUTICS INC | $6.9M | 1.35% |
| 18 | CTKB CYTEK BIOSCIENCES INC | $6.5M | 1.27% |
| 19 | CRDF CARDIFF ONCOLOGY INC | $5.9M | 1.15% |
| 20 | IMVT IMMUNOVANT INC | $4.9M | 0.95% |
Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.